



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 


PRODUCT INFORMATION



LCQ-908

Item No. 42025

CAS Registry No.: 956136-95-1
Formal Name: *trans*-4-[4-[5-[[6-(trifluoromethyl)-3-pyridinyl]amino]-2-pyridinyl]phenyl]-cyclohexaneacetic acid
Synonym: Pradigastat
MF: C₂₅H₂₄F₃N₃O₂
FW: 455.5
Purity: ≥98%
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

LCQ-908 is supplied as a solid. A stock solution may be made by dissolving the LCQ-908 in the solvent of choice, which should be purged with an inert gas. LCQ-908 is soluble (≥10 mg/ml) in DMSO.

Description

LCQ-908 is an inhibitor of diacylglycerol acyltransferase 1 (DGAT1; IC₅₀ = 57 nM).¹ It is selective for DGAT1 over DGAT2, acyl-coenzyme A:cholesterol acyltransferase-1 (ACAT-1), and ACAT-2 (IC₅₀s = >10,000 nM for all). LCQ-908 (50 μM) also inhibits hepatitis C virus (HCV) replication in HCV-infected Huh7.5 cells.² It inhibits palmitic acid-induced apoptosis and increases in triglyceride levels in MIN6 pancreatic β-cells when used at a concentration of 1 μM.³ *In vivo*, LCQ-908 (1 mg/kg) decreases serum triglyceride levels in an oral lipid tolerance test in dogs.¹

References

1. Hong, D.J., Jung, S.H., Kim, J., *et al.* Synthesis and biological evaluation of novel thienopyrimidine derivatives as diacylglycerol acyltransferase 1 (DGAT-1) inhibitors. *J. Enzyme Inhib. Med. Chem.* **35(1)**, 227-234 (2020).
2. Gane, E., Stedman, C., Dole, K., *et al.* A diacylglycerol transferase 1 inhibitor is a potent hepatitis C antiviral in vitro but not in patients in a randomized clinical trial. *ACS Infect. Dis.* **3(2)**, 144-151 (2017).
3. Huang, J.-S., Guo, B.-B., Wang, G.-H., *et al.* DGAT1 inhibitors protect pancreatic β-cells from palmitic acid-induced apoptosis. *Acta Pharmacol. Sin.* **42(2)**, 264-271 (2021).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 10/09/2024

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM